New needle probe aims to spot prostate cancer without extra tissue samples
NCT ID NCT05965180
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing a new fine needle probe that uses light and sound (photoacoustic technology) to measure prostate tissue during a standard biopsy. The probe is inserted like a regular biopsy needle but does not remove tissue. Researchers want to see if it can reliably tell the difference between healthy and cancerous areas. The study involves 50 men scheduled for a prostate biopsy.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Fine needle photoacoustic probe (device)
- What this could lead to
- If successful, this could lead to a more accurate way to detect prostate cancer during biopsy without needing extra tissue samples.
- What could go wrong
- This is a very early, small study (50 people) testing only if the device can get reliable readings. It may not show any benefit for patients, and technical failures could stop the trial early.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 50 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2023
- Expected to finish
-
Oct 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with planned prostate biopsy procedures will be recruited through U-M Urology Clinics
- Ages
-
40 to 80 years
- Sex
-
Male participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * 1\) Planned prostate biopsy as part of routine clinical care * 2\) \> 40 and \<80 years old Exclusion Criteria: * 1\) Known history of bleeding disorders or * 2\) Patients taking anticoagulants, no matter doses or washout time * 3\) Known allergy to silicone material * 4\) Unable to provide informed consent * 5\) Either the surgeon or the patient do not think the patient will not be able to complete all parts of the study, the patient will be excluded * 6\) Involved in other investigational studies.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Prostate cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University of Michigan Rogel Cancer Center
RECRUITINGAnn Arbor, Michigan, 48109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Radioactive missile aims at prostate cancer that spread
- New PET tracer targets ACP3 to spot prostate cancer
- Can a One-Week radiation course match four weeks for prostate cancer?
- Can a new PET tracer spot hidden prostate cancer spread?
- Can a gel cushion shield the rectum during prostate radiation?
- A scanner in the operating room could show surgeons exactly where prostate cancer remains